- Home
- AIRS vs FBRX Comparison
AIRS vs FBRX Comparison
Compare AIRS & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- FBRX
- Stock Information
- Founded
- AIRS 2012
- FBRX N/A
- Country
- AIRS United States
- FBRX United States
- Employees
- AIRS N/A
- FBRX N/A
- Industry
- AIRS Medical/Nursing Services
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- FBRX Health Care
- Exchange
- AIRS Nasdaq
- FBRX Nasdaq
- Market Cap
- AIRS 166.3M
- FBRX 154.5M
- IPO Year
- AIRS 2021
- FBRX N/A
- Fundamental
- Price
- AIRS $6.14
- FBRX $10.19
- Analyst Decision
- AIRS Hold
- FBRX Strong Buy
- Analyst Count
- AIRS 3
- FBRX 2
- Target Price
- AIRS $3.75
- FBRX $61.00
- AVG Volume (30 Days)
- AIRS 596.6K
- FBRX 48.0K
- Earning Date
- AIRS 08-01-2025
- FBRX 08-13-2025
- Dividend Yield
- AIRS N/A
- FBRX N/A
- EPS Growth
- AIRS N/A
- FBRX N/A
- EPS
- AIRS N/A
- FBRX N/A
- Revenue
- AIRS $172,101,000.00
- FBRX N/A
- Revenue This Year
- AIRS N/A
- FBRX N/A
- Revenue Next Year
- AIRS $4.90
- FBRX N/A
- P/E Ratio
- AIRS N/A
- FBRX N/A
- Revenue Growth
- AIRS N/A
- FBRX N/A
- 52 Week Low
- AIRS $1.53
- FBRX $4.11
- 52 Week High
- AIRS $9.20
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- AIRS 61.18
- FBRX 44.66
- Support Level
- AIRS $6.15
- FBRX $10.38
- Resistance Level
- AIRS $6.72
- FBRX $12.03
- Average True Range (ATR)
- AIRS 0.48
- FBRX 0.83
- MACD
- AIRS 0.03
- FBRX -0.04
- Stochastic Oscillator
- AIRS 66.84
- FBRX 36.66
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).